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(This paper refers to the article by
Shen and Murphy in the August issue
of Biophysical Journal.) The presence
of amyloid plaques in Alzheimer's dis-
ease (AD) suggests that amyloid for-
mation plays a major role in neurode-
generation. The major constitutive
component of amyloid plaques is the
A,B peptide, a 40- to 43-residue
polypeptide that is a cleavage product
of a larger precursor protein. A/3, as
found in plaques, is assembled into
characteristic amyloid fibrils, which
exhibit birefringent staining with
Congo red and give an x-ray fiber dif-
fraction pattern typical of the cross-,8
conformation. Under the proper condi-
tions of pH and concentration, syn-
thetic AP3 also self-assembles into
fibrils in vitro, making it relatively
easy to isolate fibrillar peptide for
study. The ease with which A,B self-
assembles into fibrils, rather than crys-
tals, makes the study of the structure of
the monomeric peptide by high-resolu-
tion methods such as NMR and x-ray
crystallography essentially impossible.
Several recent studies suggest strongly
that aggregated (fibrillar) AP3 is toxic
to neurons, while monomeric peptide
is not. While it was once believed that
AP3 was produced solely from an ab-
normal cleavage of its precursor pro-
tein, it is now known that soluble, mo-
nomeric AP3 is a normal constituent of
blood and cerebral spinal fluid. Thus,
an understanding of the processes by
which soluble AP3 is converted into
insoluble, potentially neurotoxic fibrils
is crucial to understanding the genesis
of the amyloid plaques of AD. To date,
little progress has been made in under-
standing the process of self-assembly
of AP3, but the article in the August
issue of Biophysical Journal (Shen and
Murphy, 1995) makes a significant
contribution to the current knowledge
of the conformational and kinetic
states A,3 goes through in the process
of forming fibrils.
Anyone who has ever attempted to
study the aggregation and toxicity of
A,B realizes how frustrating this pep-
tide is to deal with because of the vari-
ability of its properties. Batch-to-batch
variation even from the same source is
very common, largely because differ-
ent batches of A,B come with different
histories associated with them. In real-
ity, the pretreatment of these peptides
does a great deal toward affecting their
aggregation behavior. Shen and Mur-
phy (1995) contribute to the under-
standing of some of this erratic and
irreproducible behavior by studying
the effects of solvents on the aggrega-
tion state of the peptide using circular
dichroism (CD), Fourier transform in-
frared spectroscopy (FTMR), and light-
scattering techniques. The solvent that
the peptide is exposed to before dilu-
tion in PBS profoundly affects the ki-
netics of aggregation. Additionally, the
rate of increase of fibril formation is
directly correlated to the secondary
structure of the peptide in a stock sol-
vent. There is considerable evidence
from x-ray diffraction that A,B fibrils
derived from various A,B fragments
(Inouye et al., 1993) exist in an anti-
parallel (3-sheet conformation, while
NMR studies on AP3 fragments, Af(1-
28) in aqueous trifluoroethanol (Zagor-
ski and Barrow, 1992), suggest that the
monomeric peptide is largely helical or
random coil. Thus, understanding the
transition of A(3 from helical to
/3-sheet is vital to understanding its
self-assembly. Shen and Murphy
(1995) find that a stock solution of A,B
in 35% ACN/0.5% TFA aggregates
quickly and exhibits a significant
amount of P-sheet character (as mea-
sured by CD), leading them to surmise
that ACN acts to stabilize (3-sheet sec-
ondary structure. The predissolution in
the ACN solution causes fibrils to form
quickly and to a greater extent as mea-
sured by light scattering. From FTIR
studies, they find DMSO to be the best
at maintaining A,B in a non-/3-sheet
structure in that, upon dilution into
PBS, the A,3 forms fibrils at a slower
rate and to a lesser extent. Predissolu-
tion in 0.1% trifluoroacetate has an
intermediate affect between th DMSO
and ACN results.
A major contribution Gf thresw stud-
ies is the process of amyloid aggrega-
tion that is elucidated from these sol-
vent studies. To date, the concept of a
nucleation event (Jarrett and Lansbury,
1993) is a prevalent theory of the pro-
cess of aggregation. However, many of
the details in the nucleation theory re-
main to be elucidated. For example,
just how many monomers are neces-
sary to form a nucleus from which
fibril formation occurs quickly? The
contribution of the findings of the Shen
and Murphy (1995) paper to this ques-
tion is illustrated in Fig. 1. A monomer
converts into a /3-sheet structure, per-
haps as a dimer or 3-crystallite inter-
mediate (Inouye et al., 1993). Upon
dilution in PBS, the structure "remem-
bers" the /-sheet structure and forms
multimeric structures. Addition of this
dimeric form onto this multimer results
in fibrillar growth. Association of
these fibrils can cause fibrillar exten-
sion and, finally, these fibrils may self-
associate to form lateral aggregates or
tightly packed deposits.
Many questions still need to be re-
solved about amyloid fibrillogenesis.
Of critical importance is how aggrega-
tion in vitro compares with events that
form amyloid plaques in vivo. In this
regard, the effects of other proteins
associated with AD and amyloid
plaques such as apolipoprotein E and
glycosaminoglycans need to be further
investigated. Perhaps some of these
questions will be answered by the
emerging transgenic mice models of
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FIGURE 1 Schematic diagram il-
lustrating the association of 3-amy- Addition of,-conformation
loid peptide into fibrils as discussed 4
W W 7unit to Growing Fibril
by Shen and Murphy (1995).
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amyloid aggregation (Games et al.,
1995). While it is true that the kinetics
of the aggregation are very compli-
cated, the Shen and Murphy (1995)
study lays some important groundwork
necessary to understand the process.
The author wishes to acknowledge Dr. Dan
Kirschner, Dr. Greg Shutske, and Dr. Sudhir
Sahashrabudhe for helpful discussions.
REFERENCES
Games, D., D. Adams, R. Alessandrini, R. Bar-
bour, et al. 1995. Alzheimer-type neuropa-
thology in transgenic mice overexpressing
V717F 3-amyloid precursor protein. Nature.
373:523-527.
Inouye, H., P. E. Fraser, and D. A. Kirschner.
1993. Structure of 13-crystallite assemblies
formed by Alzheimer ,3-amyloid protein
analogues: analysis by x-ray diffraction. Bio-
phys. J. 64:502-519.
Jarrett, J. T., and P. T. Lansbury, Jr. 1993. Seed-
ing "one-dimensional crystallization" of
amyloid: a pathogenic mechanism in Alzhei-
mer's disease and scrapie? Cell. 763:
1055-1058.
Shen, C.-L., and R. M. Murphy. 1995. Solvent
effects on self-assembly of 3-amyloid pep-
tide. Biophys. J. 69:640-651.
Zagorski, M. G., and C. J. Barrow. 1992. NMR
studies of amyloid f3-peptides: proton assign-
ments, secondary structure, and mechanism of
an a-helix -> ,-sheet conversion for a homol-
ogous, 28-residue, N-terminal fragment. Bio-
chemistry. 31:5621-5631.
